Malignant Asbestos Mesothelioma Lung Cancer: News & Information

 
Mesothelioma Information
 
 
 
Search
Custom Search
Mesothelioma Lawsuits
Subscribe via Email

Enter your E-mail address

Previous Post
Archives
Live Traffic
Favorites
Add to Technorati Favorites
Subscribe to me on FriendFeed
Join My Community at MyBloglog!
http://www.wikio.com
My Zimbio
Follow Me
Catch me on Twitter
Find me through Facebook
Reach me at Orkut
Digg Profile
Stumble Me!
NeoPlas Treatment prevent the growth of cancer tumors
Monday, March 9, 2009
Recent study and research suggest that a newly, innovative cancer treatment called "NeoPlas" treatment has recently stopped the growth of aggressive sarcomas in two patients. One of the patients was diagnosed with malignant fibrous histiocytoma (MFH) and the other patient was diagnosed with desmoplastic small round cell tumor (DSRCT). After multiple surgeries and several different chemotherapy regimens had failed, the cancers were continuing to spread to other areas of their bodies. However, after just eight weeks of the NeoPlas treatment, scans revealed that both patients’ cancers had stopped spreading and some tumors had actually regressed. NeoPlas treatment is a combination of lovastatin and interferon. The treatment is also being offered for patients with colon cancer, renal cancer, melanoma, pancreatic cancer and mesothelioma. Although NeoPlas treatment is different from chemotherapy and is free of its side effects, fatigue often results in most patients.
posted by Elena @ 8:29 AM   3 comments
 Subscribe via RSS
Add to The Free Dictionary

Add to Plusmo

Subscribe in NewsAlloy

Add to Excite MIX

Add to netomat Hub

Add to fwicki

Add to Webwag

Add to Attensa

Receive IM, Email or Mobile alerts when new content is published on this site.
Forum Discussion
Discussion board for asbestos mesothelioma lung cancer and its treatments
Mesothelioma Treatment
Links
News Feed Widget

Alexa Rank
Powered by
BLOGGER
Copyright © 2009 Malignant Asbestos Mesothelioma Lung Cancer: News & Information. All rights reserved